MolecularMD Enters Into a Collaboration Agreement With Illumina for Drug-Diagnostic Co-Development With Biopharma Drug Programs
Get Alerts ILMN Hot Sheet
Join SI Premium – FREE
PORTLAND, OR and CAMBRIDGE, MA -- (Marketwired) -- 06/27/16 -- MolecularMD Corporation announced today that it has entered into an agreement with Illumina, Inc. (NASDAQ: ILMN) that establishes a framework for potential collaborations with respect to the development and commercialization of sequencing-based companion diagnostics in support of biopharma drug development program(s). The agreement dovetails MolecularMD's companion diagnostic development and FDA submission experience with Illumina's NGS technology.
"This agreement is designed to deliver the combined power of Illumina's NGS technologies with MolecularMD's ability to tailor a complete clinical development solution including regulatory planning, IDE validations and centralized testing and data management for global patient enrollment and disease monitoring," stated Dan Snyder, CEO of MolecularMD.
MolecularMD opened its advanced diagnostic laboratory in Cambridge, MA in 2012 with the objective of providing NGS solutions that support clinical trials of oncology drug programs. MolecularMD has since deployed NGS diagnostics over a broad range of drug targets and indications. The ability to support global trials with centralized testing laboratories while simultaneously obtaining necessary regulatory compliance can allow rapid deployment of Illumina based NGS solutions.
"Our goal is to enable our clients with the latest platforms and proven technologies that solve for the challenges that often arise during drug and diagnostic co-development," stated Snyder. "The ability to collaborate with Illumina on defined projects will greatly aid our clients to mitigate risks and to accelerate their clinical trial programs."
About MolecularMD
MolecularMD Corporation develops and commercializes specialty molecular diagnostics for oncology applications. Tests are designed to allow appropriate selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. MolecularMD integrates gold-standard and innovative platform technologies with clinical assay design, validation and centralized testing to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents.
Media Inquiries:Tina BeaucheminMolecularMD(617) 575-2824 [email protected]
Source: MolecularMD
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GRAIL Presents New Data on GalleriĀ® and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting
- Sungrow Powers Its Way into the Prestigious 2024 Fortune Asia Future 30
- Bilibili Inc. Announces Completion of the Repurchase Right Offer for 1.375% Convertible Senior Notes due 2026
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!